A2073

Overview

A2073 is a flavagline derivative that potently inhibits the proliferation of erythroleukemia cells by causing cell cycle arrest and suppressing the MAPK , NF-κB , and PI3K signaling pathways. A2073 formes stable interactions with cell cycle-related proteins ( CDK1 , CCNA2, PRIM1). A2073 exhibits significant anti-proliferative activity against tumor cells while maintaining a favorable toxicity profile in a zebrafish xenograft tumor model. A2073 can be used for the study of acute erythroleukemia.

Application

Products | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > NF-κB | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Akt | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-174321
• CAS No.: 2834742-70-8
• Molecular Formula: C33H37NO7
• Molecular Weight: 559.65
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source